John H. Tucker
president and chief executive officer
John H. Tucker is the chief executive officer of scPharmaceuticals. Prior to scPharmaceuticals, Mr. Tucker served as chief executive officer of Algal Scientific, a developer of auto-immune products. There he repositioned the company and successfully negotiated its sale. Prior to Algal, he served as chief executive officer at Alcresta, a developer of enzyme-based products for patients with acute and chronic diseases. While at Alcresta he led regulatory and financing strategies leading to its first product approval and increased valuation. Prior to Alcresta, he served as senior vice president and chief commercial officer of Incline Therapeutics, a hospital-focused specialty pharmaceutical company. There, he developed and drove the overall commercial strategy in support of the company’s lead product, IONSYS™, resulting in a $390 million purchase of Incline by The Medicines Company. He joined Incline from AMAG Pharmaceuticals, where he was senior vice president, commercial operations, responsible for all sales and marketing activities for the company. Previously, as president, U.S. operations at Basilea Pharmaceuticals, Mr. Tucker developed the strategy and organization for the planned launch of a hospital-focused product and led the company’s commercial development team. Prior to Basilea, Mr. Tucker was executive vice president, sales and marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS and UCB Pharma. Mr. Tucker holds a B.A. from Plymouth State College and an MBA from New Hampshire College.
chief operating officer
Abraham Ceesay is the Chief Operating Office at scPharmaceuticals responsible for manufacturing, technical operations, engineering, and commercial aspects of the business. Mr. Ceesay has a strong track record of commercializing innovative therapeutic products and leading development stage organizations to commercial stage companies. Prior to joining scPharmaceuticals, Mr. Ceesay served as vice president, sales, marketing, and commercial operations at Keryx Biopharmaceuticals where he developed the commercial organization and strategy for the company’s inaugural product Auryxia®. Prior to Keryx, Mr. Ceesay spent four years at Ironwood Pharmaceuticals as vice president, marketing, where he led the launch of the company’s inaugural product Linzess® and held responsibility for the management of the US P&L, leadership of the Linzess® brand team and co-promotion collaboration with Forest Laboratories/Allergan. Mr. Ceesay also spent eight years at Genzyme/Sanofi, where he was responsible for the US marketing of Synvisc® and Carticel® as well as the global launch of Renvela®. Mr. Ceesay serves on the Board of Advisors for Life Science Cares and the Board of Directors for Food for Free. Mr. Ceesay holds a bachelor’s degree from Ithaca College, and a Masters of Business Administration from Suffolk University’s Sawyer School of Management.
chief financial officer
Troy Ignelzi is a senior financial executive with more than 20 years experience in finance, operations and business development with start-up and established companies. Mr. Ignelzi has raised over $300 million in private/public equity and debt, in-licensed commercial technology and completed extensive investor outreach. Prior to scPharmaceuticals, Troy served as a member of the executive leadership teams at Juventas Therapeutics, Esperion Therapeutics (ESPR) and Insys Therapeutics (INSY) where he successfully led various equity and debt financings to fund pharmaceutical and drug device development from pre-IND through commercialization. Troy holds a B.S. Accounting from Ferris State University, MI.